Biome Diagnostics GmbH, also known as BiomeDx, is an Austrian-based MedTech company that is revolutionizing cancer care through its pioneering microbiome-based technologies. This innovative company is at the forefront of the intersection between cutting-edge DNA sequencing and advanced machine learning algorithms, developing groundbreaking technologies for routine clinical practice. As the world's first microbiome company to be certified according to ISO 13485:2016 and ISO 9001:2015, BiomeDx is committed to advancing precision medicine.

By understanding and linking microbial functions with complex biological metadata, such as human diversity and health status, BiomeDx aims to decipher one of today's most challenging approaches to precision cancer treatments. With a vision to build world-class microbiome diagnostics and therapeutics, BiomeDx combines microbiome diagnostics and well-tested machine learning models. Founded by Dr.

Barbara Sladek and Dr. Nikolaus Gasche, both with extensive scientific and business expertise, BiomeDx is revolutionizing healthcare and medicine by integrating next-generation microbiome-based technologies. Supported by a senior advisory board consisting of experts in microbiome research, pharma, technology, and finance, BiomeDx is proud to work on paradigm-changing technologies based on a fundamental understanding of the intestinal microbiome and proprietary artificial intelligence models.

Join BiomeDx in their mission to advance precision medicine and transform cancer care. Stay updated with their progress and get early access to their innovative diagnostic products